{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:12:18Z","timestamp":1787501538786,"version":"build-2736575974"},"reference-count":45,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>This review aimed to provide a comprehensive overview of the current landscape of etrasimod. Etrasimod is an oral, once-daily selective modulator of sphingosine 1-phosphate receptors (S1PR), developed for the treatment of moderately to severely active ulcerative colitis and currently being explored for its potential in other immune-mediated inflammatory diseases. It selectively targets the S1PR subtypes S1PR1, S1PR4, and S1PR5, with limited activity on S1PR3 and no activity on S1PR2. Clinical trials have demonstrated that etrasimod significantly reduces symptoms and induces endoscopic improvement in patients with moderate to severe ulcerative colitis who are refractory or intolerant to at least one conventional therapy, biologic agent, or Janus kinase inhibitor, while maintaining a favourable safety profile. At the end of 2023, etrasimod was approved in the United States and Europe, and it is currently under review for ulcerative colitis in several other regions. Etrasimod offers a novel therapeutic option with unique characteristics that may help address the persistent unmet needs of real-world patients with moderately to severely active ulcerative colitis.<\/jats:p>","DOI":"10.3390\/jcm14113890","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T10:21:49Z","timestamp":1748859709000},"page":"3890","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Etrasimod: Modulating Sphingosine-1-Phosphate Receptors to Treat Ulcerative Colitis"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5079-613X","authenticated-orcid":false,"given":"Cristina","family":"Martinez-Molina","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Division of Medicines, Hospital Cl\u00ednic de Barcelona, Villarroel 170, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9566-5993","authenticated-orcid":false,"given":"Bego\u00f1a","family":"Gonz\u00e1lez-Su\u00e1rez","sequence":"additional","affiliation":[{"name":"Endoscopy Unit, Department of Gastroenterology, Clinical Institute of Digestive and Metabolic Diseases (ICMDM), Hospital Cl\u00ednic de Barcelona, Villarroel 170, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(23)00966-2","article-title":"Ulcerative colitis","volume":"402","author":"Honap","year":"2023","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41572-020-0205-x","article-title":"Ulcerative colitis","volume":"6","author":"Kobayashi","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Liang, Y., Li, Y., Lee, C., Yu, Z., Chen, C., and Liang, C. (2024). Ulcerative colitis: Molecular insights and intervention therapy. Mol. Biomed., 5.","DOI":"10.1186\/s43556-024-00207-w"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"100851","DOI":"10.1016\/j.disamonth.2019.02.004","article-title":"A comprehensive review and update on ulcerative colitis","volume":"65","author":"Gajendran","year":"2019","journal-title":"Dis. Mon."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J. Crohns. Colitis"},{"key":"ref_8","unstructured":"European Medicines Agency (EMA) (2025, January 11). Remsima (Infliximab), Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/remsima."},{"key":"ref_9","unstructured":"European Medicines Agency (EMA) (2025, January 11). Amgevita (Adalimumab), Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/amgevita."},{"key":"ref_10","unstructured":"European Medicines Agency (EMA) (2025, January 11). Simponi (Golimumab), Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/simponi."},{"key":"ref_11","unstructured":"European Medicines Agency (EMA) (2025, January 11). Entyvio (Vedolizumab), Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/entyvio."},{"key":"ref_12","unstructured":"European Medicines Agency (EMA) (2025, January 11). Stelara, Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/stelara."},{"key":"ref_13","unstructured":"European Medicines Agency (EMA) (2025, January 11). Omvoh (Mirikizumab), Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/omvoh."},{"key":"ref_14","unstructured":"European Medicines Agency (EMA) (2025, January 11). Skyrizi (Risankizumab), Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/skyrizi."},{"key":"ref_15","unstructured":"European Medicines Agency (EMA) (2025, January 11). Xeljanz (Tofacitinib), Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/xeljanz."},{"key":"ref_16","unstructured":"European Medicines Agency (EMA) (2025, January 11). Rinvoq (Upadacitinib), Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/rinvoq."},{"key":"ref_17","unstructured":"European Medicines Agency (EMA) (2025, January 11). Jyseleca (Filgotinib), Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/jyseleca."},{"key":"ref_18","unstructured":"European Medicines Agency (EMA) (2025, January 11). Zeposia (Ozanimod), Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zeposia."},{"key":"ref_19","unstructured":"European Medicines Agency (EMA) (2025, January 11). Velsipity (Etrasimod), Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/velsipity."},{"key":"ref_20","unstructured":"U.S. Food & Drug Administration (FDA) (2025, January 11). Velsipity (Etrasimod), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/216956s000lbl.pdf#page=24."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): Two randomised, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"Sandborn","year":"2023","journal-title":"Lancet"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s40265-024-02094-5","article-title":"Targeting the Sphingosine-1-Phosphate Pathway: New Opportunities in Inflammatory Bowel Disease Management","volume":"84","author":"Kitsou","year":"2024","journal-title":"Drugs"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1212\/WNL.0b013e31820d5ec1","article-title":"Sphingosine 1-phosphate (S1P): Physiology and the effects of S1P receptor modulation","volume":"76","author":"Hla","year":"2011","journal-title":"Neurology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2217\/imt-2022-0255","article-title":"Etrasimod for the treatment of ulcerative colitis","volume":"15","author":"Wils","year":"2023","journal-title":"Immunotherapy"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/S0140-6736(21)00244-0","article-title":"Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions","volume":"398","author":"McGinley","year":"2021","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/mi.2016.35","article-title":"Sphingosine-1-phosphate receptor-1 (S1P1) is expressed by lymphocytes, dendritic cells, and endothelium and modulated during inflammatory bowel disease","volume":"10","author":"Karuppuchamy","year":"2017","journal-title":"Mucosal Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1124\/pr.107.07113","article-title":"\u201cInside-out\u201d signaling of sphingosine-1-phosphate: Therapeutic targets","volume":"60","author":"Takabe","year":"2008","journal-title":"Pharmacol. Rev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1194\/jlr.M034108","article-title":"S1P\u2081 localizes to the colonic vasculature in ulcerative colitis and maintains blood vessel integrity","volume":"54","author":"Montrose","year":"2013","journal-title":"J. Lipid Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.autrev.2017.03.007","article-title":"Modulation of sphingosine-1-phosphate in inflammatory bowel disease","volume":"16","author":"Christopher","year":"2017","journal-title":"Autoimmun. Rev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1080\/14712598.2020.1732919","article-title":"Modulation of sphingosine-1-phosphate in ulcerative colitis","volume":"20","author":"Argollo","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/17474124.2020.1709446","article-title":"Is there a role for therapeutic sphingolipids in inflammatory bowel disease?","volume":"14","author":"Parigi","year":"2020","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_32","unstructured":"U.S. Food & Drug Administration (FDA) (2025, January 12). Gilenya (Fingolimod), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/022527s042lbl.pdf#page=26."},{"key":"ref_33","unstructured":"European Medicines Agency (EMA) (2025, January 12). Gilenya (Fingolimod), Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/gilenya."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","article-title":"Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): A double-blind, randomised, placebo-controlled, phase 3 trial","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4062\/biomolther.2016.160","article-title":"Sphingosine 1-Phosphate Receptor Modulators and Drug Discovery","volume":"25","author":"Park","year":"2017","journal-title":"Biomol. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Lee, J.H., Lee, J.E., and Im, D.S. (2024). Blocking the Sphingosine-1-Phosphate Receptor 2 (S1P2) Reduces the Severity of Collagen-Induced Arthritis in DBA-1J Mice. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252413393"},{"key":"ref_37","unstructured":"U.S. Food & Drug Administration (FDA) (2025, January 12). Zeposia (Ozanimod), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/209899s013s014lbl.pdf#page=27."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S1474-4422(16)00018-1","article-title":"Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): A randomised, placebo-controlled, phase 2 trial","volume":"15","author":"Cohen","year":"2016","journal-title":"Lancet Neurol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1124\/jpet.118.254268","article-title":"The Selective Sphingosine 1-Phosphate Receptor Modulator Etrasimod Regulates Lymphocyte Trafficking and Alleviates Experimental Colitis","volume":"369","author":"Carroll","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_40","unstructured":"PubChem [Internet] (2025, January 12). Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information. PubChem Compound Summary for CID 44623998, Etrasimod, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Etrasimod."},{"key":"ref_41","unstructured":"Clinical Trials [Internet] (2025, January 22). Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information. Etrasimod, Available online: https:\/\/clinicaltrials.gov\/search?intr=etrasimod&viewType=Table&limit=100&page=1."},{"key":"ref_42","unstructured":"AdisInsight [Internet] (2025, January 22). Springer Nature: Springer Nature Switzerland AG. Etrasimod. Available online: https:\/\/adisinsight.springer.com\/drugs\/800037849."},{"key":"ref_43","unstructured":"European Medicines Agency (EMA) (2025, January 28). Janus Kinase Inhibitors (JAKi)\u2014Referral [Internet]. The Netherlands, Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/janus-kinase-inhibitors-jaki."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_45","first-page":"1","article-title":"The role of immunogenicity in optimizing biological therapies for inflammatory bowel disease","volume":"25","author":"Sharma","year":"2025","journal-title":"Expert Rev. Gastroenterol. Hepatol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/11\/3890\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:45:19Z","timestamp":1760031919000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/11\/3890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,1]]},"references-count":45,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["jcm14113890"],"URL":"https:\/\/doi.org\/10.3390\/jcm14113890","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,1]]}}}